Annual Revenue Comparison: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.

Ionis vs. BioCryst: A Decade of Revenue Dynamics

__timestampBioCryst Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.
Wednesday, January 1, 201413608000214161000
Thursday, January 1, 201548257000283703000
Friday, January 1, 201626353000346620000
Sunday, January 1, 201725186000507666000
Monday, January 1, 201820653000599674000
Tuesday, January 1, 2019488350001123000000
Wednesday, January 1, 202017812000729000000
Friday, January 1, 2021157170000810000000
Saturday, January 1, 2022270827000587000000
Sunday, January 1, 2023331412000787647000
Monday, January 1, 2024705138000
Loading chart...

Cracking the code

A Decade of Revenue Growth: Ionis vs. BioCryst

In the competitive landscape of biotechnology, Ionis Pharmaceuticals and BioCryst Pharmaceuticals have showcased intriguing revenue trajectories over the past decade. From 2014 to 2023, Ionis Pharmaceuticals consistently outperformed BioCryst, with revenues peaking at approximately $788 million in 2023, marking a 268% increase from 2014. In contrast, BioCryst's revenue growth was more modest, reaching around $331 million in 2023, a significant leap from its 2014 revenue, yet still trailing behind Ionis.

Key Insights

  • Ionis Pharmaceuticals: Demonstrated robust growth, particularly between 2018 and 2019, with a revenue surge of nearly 87%.
  • BioCryst Pharmaceuticals: Despite a slower start, the company saw a remarkable 110% increase in revenue from 2021 to 2023.

This comparison highlights the dynamic nature of the biotech industry, where strategic innovation and market adaptation are crucial for sustained growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025